Changes in Microbiome Predict Risk for Sexually Transmitted Infections | Newswise

Changes in Microbiome Predict Risk for Sexually Transmitted Infections | Newswise

Specific changes in the cervicovaginal microbiome set the stage for chlamydia Findings in women of color, disproportionately affected by infections but understudied Team reveals previously unknown subtype of BV, bacterial vaginosis January 15, 2025—(BRONX, NY and BUFFALO, NY)—Women who develop bacterial vaginosis (BV) often later acquire chlamydia, a common and potentially serious sexually transmitted bacterial…

Read More
Roswell Park Team Identifies New Cause of Chemotherapy Resistance in Triple-Negative Breast Cancer | Newswise

Roswell Park Team Identifies New Cause of Chemotherapy Resistance in Triple-Negative Breast Cancer | Newswise

  One of the deadliest types of breast cancer, TNBC has a high recurrence rate Study shows IMPDH2 inhibitors reduce growth of chemo-resistant tumors Findings published in Nature’s Scientific Reports BUFFALO, N.Y. — Triple-negative breast cancer, or TNBC, presents numerous treatment challenges. Compared with other forms of breast cancer, it’s more likely to have spread…

Read More
Roswell Park Team Discovers New Treatment Target f | Newswise

Roswell Park Team Discovers New Treatment Target f | Newswise

Findings from new preclinical study reported in Oncogene Work helps explain why advanced prostate tumors may resist current treatments HSP60 inhibition emerges as promising treatment strategy BUFFALO, N.Y. — A team of researchers at Roswell Park Comprehensive Cancer Center, led by Dhyan Chandra, PhD, has discovered a new therapeutic target for neuroendocrine prostate cancer, a rare…

Read More
Roswell Park Study Reveals How Venetoclax Boosts I | Newswise

Roswell Park Study Reveals How Venetoclax Boosts I | Newswise

Newswise — BUFFALO, N.Y. — Research out of Roswell Park Comprehensive Cancer Center has shed light on how the drug venetoclax (brand name Venclexta) works synergistically with CAR T-cell immunotherapy to combat chronic lymphocytic leukemia (CLL), the most common type of leukemia in the U.S. Matthew Cortese, MD, MPH, Assistant Professor of Oncology in Roswell Park’s departments of Medicine…

Read More